Patents Assigned to Kowa Co., Ltd.
  • Patent number: 9045460
    Abstract: The present invention provides a method capable of industrially producing a target product, i.e., a compound represented by the aforementioned formula (I) or a salt thereof, which is useful for preventing and treating cerebrovascular disorders such as cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, and cerebral edema, particularly for preventing and treating glaucoma, at high yield even on a large scale without imposing a negative impact on the environment. The present invention provides a method for producing a compound represented by formula (I) or a salt thereof, wherein the method comprises a step of reacting a compound represented by formula (III) or a salt thereof with a compound represented by formula (II) in the presence of at least one solvent selected from the group consisting of a nitrile solvent, an amide solvent, a sulfoxide solvent, and a urea solvent, and a base.
    Type: Grant
    Filed: August 25, 2011
    Date of Patent: June 2, 2015
    Assignee: KOWA CO., LTD.
    Inventors: Noriaki Gomi, Tadaaki Ohgiya, Kimiyuki Shibuya
  • Patent number: 9039167
    Abstract: The present invention has a technical object to provide glasses which prevent invasion of pollen, can be continuously worn without any discomfort in wearing, and can effectively block ultraviolet ray. The present invention achieves the technical object by glasses including inwardly projecting visors in rims and end pieces of a frame, and glasses in which lenses, a frame, and inwardly projecting visors formed in the frame are formed of synthetic resin containing an ultraviolet absorbing agent or an ultraviolet scattering agent.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: May 26, 2015
    Assignee: KOWA CO., LTD.
    Inventors: Yoshihiro Miwa, Tadashi Kita
  • Publication number: 20150087824
    Abstract: The present invention provides a method capable of industrially producing a target product, i.e., a compound represented by the aforementioned formula (I) or a salt thereof, which is useful for preventing and treating cerebrovascular disorders such as cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, and cerebral edema, particularly for preventing and treating glaucoma, at high yield even on a large scale without imposing a negative impact on the environment. The present invention provides a method for producing a compound represented by formula (I) or a salt thereof, wherein the method comprises a step of reacting a compound represented by formula (III) or a salt thereof with a compound represented by formula (II) in the presence of at least one solvent selected from the group consisting of a nitrile solvent, an amide solvent, a sulfoxide solvent, and a urea solvent, and a base.
    Type: Application
    Filed: December 5, 2014
    Publication date: March 26, 2015
    Applicant: KOWA CO., LTD.
    Inventors: Noriaki GOMI, Tadaaki OHGIYA, Kimiyuki SHIBUYA
  • Patent number: 8969378
    Abstract: The present invention is to provide an inhibitor that inhibits differentiation of T cells into Th1 cells. The inhibitor that inhibits differentiation of T cells into Th1 cells contains, as an active ingredient, pitavastatin or a salt thereof.
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: March 3, 2015
    Assignees: Kowa Co., Ltd., National University Corporation Nagoya University
    Inventor: Akio Suzumura
  • Patent number: 8853273
    Abstract: The present invention relates to provision of a pharmaceutical agent useful for the prevention and treatment of hepatocellular carcinoma, and the pharmaceutical agent for the prevention and/or treatment of hepatocellular carcinoma contains an acyclic retinoid, a salt thereof, or a solvate of any of these, in combination with a branched-chain amino acid, a salt thereof, or a solvate of any of these.
    Type: Grant
    Filed: August 10, 2011
    Date of Patent: October 7, 2014
    Assignee: Kowa Co., Ltd.
    Inventors: Ken Uesugi, Tetsuro Sano, Takatoshi Ozawa, Kazuhide Shimada
  • Patent number: 8834887
    Abstract: To provide a drug for actively metabolizing or excreting a pathogen occurring in vivo. The present invention is directed to a compound which is formed of (A) an adsorbent for a pathogen occurring in the blood or lymph, and (B) a ligand which is specific to an organ or cells capable of metabolizing or excreting the pathogen and which is bonded to the adsorbent via a linker or with no linker, and to a drug containing the same.
    Type: Grant
    Filed: September 25, 2008
    Date of Patent: September 16, 2014
    Assignees: National Cerebral and Cardiovascular Center, Kowa Co., Ltd.
    Inventors: Tetsuji Yamaoka, Mariko Shiba, Atsushi Mahara, Yoshihito Kato
  • Patent number: 8765771
    Abstract: The present invention relates to provision of a novel compound that has an activity of promoting insulin secretion from pancreatic ? cells and thus is useful as a prophylaxis and/or therapeutic agent for diseases caused by hyperglycemia such as diabetes mellitus, and the compound represented by the following formula (1): wherein one of A and B represents a nitrogen atom and the other represents a nitrogen atom or CR10, X represents an oxygen atom, a sulfur atom or —(CH2)n-N(R12)—, Y represents an oxygen atom, a sulfur atom or —N(R13)—, and R1 to R9 each represent a hydrogen atom or another substituent, or a salt thereof, or a solvate of the compound or the salt.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: July 1, 2014
    Assignee: Kowa Co., Ltd.
    Inventors: Toshiharu Morimoto, Tomoaki Koshizawa, Gen Watanabe, Tadaaki Ohgiya, Nao Yamasaki, Noriyuki Inoue
  • Publication number: 20140094451
    Abstract: There is provided a preventive for glaucoma or a preventive or a remedy for ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. A preventive or a remedy for glaucoma comprising a Rho kinase inhibitor and an ?1 blocker in combination.
    Type: Application
    Filed: December 6, 2013
    Publication date: April 3, 2014
    Applicant: Kowa Co., Ltd.
    Inventors: Ken MIZUNO, Jiro MATSUMOTO
  • Patent number: 8685952
    Abstract: The present invention provides a method for treatment of diabetes, comprising administering a pitavastatin, and in combination therewith, enalapril or a salt thereof.
    Type: Grant
    Filed: June 29, 2006
    Date of Patent: April 1, 2014
    Assignees: KOWA Co., Ltd., Nissan Chemical Industries, Ltd.
    Inventors: Taro Aoki, Katsutoshi Miyosawa
  • Patent number: 8673960
    Abstract: The present invention provides an indomethacin-containing external liquid preparation which provides good feeling of use, which exhibits high percutaneous absorption of indomethacin, and which, particularly in a low-temperature environment, does not cause precipitation of crystals with time. The present invention is drawn to an external liquid preparation containing indomethacin, a lower alcohol, water, a sulfite, and polyethylene glycol having an average molecular weight of 3,000 to 15,000.
    Type: Grant
    Filed: October 16, 2006
    Date of Patent: March 18, 2014
    Assignee: Kowa Co., Ltd.
    Inventors: Hiroshi Miura, Makoto Kanebako
  • Patent number: 8629161
    Abstract: There is provided a preventive for glaucoma or a preventive or a remedy for ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. A preventive or a remedy for glaucoma comprising a Rho kinase inhibitor and an ?1 blocker in combination.
    Type: Grant
    Filed: June 20, 2006
    Date of Patent: January 14, 2014
    Assignee: Kowa Co., Ltd.
    Inventors: Ken Mizuno, Jiro Matsumoto
  • Patent number: 8604054
    Abstract: The present invention is directed to a triglyceride-lowering agent, exhibiting excellent triglyceride-lowering effect and a hyperinsulinemia-ameliorating agent. The triglyceride-lowering agent and hyperinsulinemia-ameliorating agent are characterized by containing a pitavastatin compound, and amlodipine or a salt thereof.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: December 10, 2013
    Assignees: Kowa Co., Ltd., Nissan Chemical Industries, Ltd.
    Inventors: Toru Yokoyama, Taro Aoki
  • Publication number: 20130310370
    Abstract: There is provided a drug therapy for prevention of glaucoma or prevention or treatment of ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. Disclosed is a combination of (S)-(?)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate thereof, and a prostaglandin for prevention or treatment of glaucoma.
    Type: Application
    Filed: February 3, 2012
    Publication date: November 21, 2013
    Applicant: KOWA CO., LTD.
    Inventor: Ken Mizuno
  • Publication number: 20130225618
    Abstract: The present invention is intended to provide a pharmaceutical product for inhibiting expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, the present invention is also intended to provide a preventive and/or therapeutic agent for various diseases based on inhibition of expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, and the present invention relates to an agent for inhibiting expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, and relates also to a preventive and/or therapeutic agent for various diseases based on the inhibition of the expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, the agent comprising a compound represented by Formula (I), its salt, or a solva
    Type: Application
    Filed: October 3, 2011
    Publication date: August 29, 2013
    Applicant: KOWA CO., LTD.
    Inventors: Kimiyuki Shibuya, Tadaaki Ohgiya, Takeshi Murakami
  • Patent number: 8518936
    Abstract: Monohydrochloride acid addition salts of a polyacidic basic compound, or a water adduct having basic site(s) stronger than pyridine. These monohydrochlorides can be produced by reacting a polyacidic basic compound with an acid salt of pyridine.
    Type: Grant
    Filed: April 16, 2010
    Date of Patent: August 27, 2013
    Assignee: Kowa Co., Ltd.
    Inventors: Kimiyuki Shibuya, Tadaaki Ohgiya, Takayuki Matsuda
  • Publication number: 20130210860
    Abstract: Provided is a new prophylactic and/or therapeutic agent for lymphedema, for which until now there has been no effective means of treatment, and the prophylactic and/or therapeutic agent for lymphedema comprises, as an active ingredient, a compound represented by the following formula (1), a lactone derivative thereof, or a salt of the compound or lactone derivative: wherein R1 represents an organic group, X represents —CH2CH2— or —CH=CH—, and R2 represents a hydrogen atom or an alkyl group.
    Type: Application
    Filed: October 5, 2011
    Publication date: August 15, 2013
    Applicants: KOWA CO., LTD., THE UNIVERSITY OF TOKYO
    Inventors: Ichiro Manabe, Ryozo Nagai, Fusa Ogata
  • Publication number: 20130177655
    Abstract: A preventing or treating agent for glaucoma is provided. This drug has a strong action of reducing intraocular pressure such that the intraocular pressure can be reduced even from the normal intraocular pressure. More specifically, a prophylactic or therapeutic agent for glaucoma, a preventing or treating agent for ocular hypertension, and eye drops containing (S)-(?)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl homopiperazine or its salt and phosphoric acid or its salt are provided.
    Type: Application
    Filed: March 4, 2013
    Publication date: July 11, 2013
    Applicant: Kowa Co., Ltd.
    Inventor: Kowa Co., Ltd.
  • Publication number: 20130123363
    Abstract: The present invention relates to provision of a pharmaceutical agent useful for the prevention and treatment of hepatocellular carcinoma, and the pharmaceutical agent for the prevention and/or treatment of hepatocellular carcinoma contains an acyclic retinoid, a salt thereof, or a solvate of any of these, in combination with a branched-chain amino acid, a salt thereof, or a solvate of any of these.
    Type: Application
    Filed: August 10, 2011
    Publication date: May 16, 2013
    Applicant: KOWA CO., LTD.
    Inventors: Ken Uesugi, Tetsuro Sano, Takatoshi Ozawa, Kazuhide Shimada
  • Patent number: 8442629
    Abstract: Provided is to enhance the therapeutic effect of an iontophoretic preparation for treatment of breast cancer or mastitis. An iontophoretic preparation for treatment of breast cancer and/or mastitis containing, as an active ingredient, a nonsteroidal anti-inflammatory analgesic agent and/or an anticancer agent, wherein an electrolyte is topically administered through the nipple part into the mammary gland; subsequently, a donor is applied to the nipple part; and the active ingredient is topically administered through the nipple part into the mammary gland by application of current.
    Type: Grant
    Filed: April 17, 2009
    Date of Patent: May 14, 2013
    Assignee: Kowa Co., Ltd.
    Inventors: Kenichi Suzuki, Makoto Kanebako, Toshio Inagi
  • Publication number: 20130102621
    Abstract: The present invention relates to provision of a novel compound that has an activity of promoting insulin secretion from pancreatic ? cells and thus is useful as a prophylaxis and/or therapeutic agent for diseases caused by hyperglycemia such as diabetes mellitus, and the compound represented by the following formula (1): wherein one of A and B represents a nitrogen atom and the other represents a nitrogen atom or CR10, X represents an oxygen atom, a sulfur atom or —(CH2)n-N(R12)—, Y represents an oxygen atom, a sulfur atom or —N(R13)—, and R1 to R9 each represent a hydrogen atom or another substituent, or a salt thereof, or a solvate of the compound or the salt.
    Type: Application
    Filed: June 24, 2011
    Publication date: April 25, 2013
    Applicant: KOWA CO., LTD.
    Inventors: Toshiharu Morimoto, Tomoaki Koshizawa, Gen Watanabe, Tadaaki Ohgiya, Nao Yamasaki, Noriyuki Inoue